ACORDA THERAPEUTICS INC (ACOR) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 1000 transactions totaling $186.5M, demonstrating a bearish sentiment with -$156.3M in net insider flow. The most recent transaction on Mar 17, 2023 involved a purchase of 10,000 shares valued at $6.5K.
No significant insider buying has been recorded for ACOR in the recent period.
No significant insider selling has been recorded for ACOR in the recent period.
Based on recent SEC filings, insider sentiment for ACOR is bearish with an Insider Alignment Score of 8/100 and a net flow of -$156.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ACORDA THERAPEUTICS INC (ACOR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading ACOR stock, having executed 1000 transactions in the past 90 days. The most active insider is Management, Inc. Scopia (Executive), who has made 17 transactions totaling $38.2M.
Get notified when executives and directors at ACOR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | Cohen Ron | Executive | Purchase | 10,000 | $0.65 | $6.5K | |
| Mar 16, 2023 | Cohen Ron | Executive | Purchase | 10,156 | $0.60 | $6.1K | |
| Sep 3, 2022 | M. Clem Kerry | Executive | Payment | 1,511 | $0.40 | $604 | |
| Sep 3, 2022 | M. Sabella Lauren | Executive | Payment | 1,511 | $0.40 | $604 | |
| Mar 17, 2022 | Cohen Ron | Executive | Sale | 2,289 | $1.70 | $3.9K | |
| Sep 3, 2021 | Cohen Ron | Executive | Payment | 3,940 | $4.38 | $17.3K | |
| Sep 3, 2021 | Morales Robert | Executive | Payment | 448 | $4.38 | $2.0K | |
| Sep 3, 2021 | M. Sabella Lauren | Executive | Payment | 1,511 | $4.38 | $6.6K | |
| Mar 3, 2021 | Blank Burkhard | Executive | Award | 11,125 | $N/A | $0 | |
| Mar 3, 2021 | Cohen Ron | Executive | Award | 29,000 | $N/A | $0 | |
| Mar 3, 2021 | M. Sabella Lauren | Executive | Award | 11,125 | $N/A | $0 | |
| Dec 1, 2020 | Lawrence David | Executive | Payment | 1,141 | $0.65 | $742 | |
| Nov 9, 2020 | Lawrence David | Executive | Payment | 1,024 | $0.86 | $881 | |
| Sep 17, 2020 | Blank Burkhard | Executive | Award | 3,015 | $N/A | $0 | |
| Sep 17, 2020 | Cohen Ron | Executive | Award | 8,543 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 765 | $171.4M | 81.4% |
Exercise(M) | 114 | $22.4M | 10.7% |
Purchase(P) | 6 | $15.1M | 7.2% |
Payment(F) | 24 | $1.7M | 0.8% |
Award(A) | 90 | $30.0K | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at ACORDA THERAPEUTICS INC has increased, with 24 insiders executing 1000 transactions across all time. Total sales of $171.4M significantly outpace purchases of $15.1M, resulting in a net outflow of $156.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.